“Donepezil patch filing on track for early 2019 filing. Owing to a previously disclosed need to conduct 12-month stability testing with the patch size used in the pilot BE study, the NDA filing is expected to occur in early calendar 1Q19. In the meantime, the company is conducting ancillary testing needed for approval, e.g., skin tolerability, alternative patch application site and heat effect studies. Notwithstanding the slight filing push, we believe it reasonable that the patch could be approved before the end of 2019.”
According to TipRanks.com, Tanner is a 4-star analyst with an average return of 8.6% and a 53.8% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Supernus Pharmaceuticals, and Intra-Cellular Therapies.
Corium has an analyst consensus of Moderate Buy, with a price target consensus of $14.
Based on Corium’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $13.29 million. In comparison, last year the company had a GAAP net loss of $11.04 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Corium International, Inc. is a commercial stage biopharmaceutical company, which develops, manufactures and commercializes pharmaceutical products. The company development platforms enable transdermal delivery of large molecules or biologics, including vaccines, peptides and proteins, as well as small molecules that are otherwise difficult to deliver in a transdermal dosage form. The firm offers its products under the brands Corplex and MicroCor. Corium International was founded by Gary W. Cleary and Adrian L. Faasse, Jr. in 1999 and is headquartered in Menlo Park, CA.